Research Article
Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
Table 3
PD-L1/PD-1 coexpression with CXCR3/CD36 and IL-19 in different lymphoma patients’ outcomes. CR: complete remission; PR: partial remission; refractory: therapy resistance; post-T: posttherapy; IQR: interquartile range; pre-T: pretherapy.
identifies highly significant differences
; identifies significant differences
.
| | | CR
I | PR
II | Relapse III | Refractory IV | I vs. II | I vs. III | I vs. IV | II vs. III | II vs. IV | III vs. IV |
| | Pre-T IL-19 (pg/ml) | Median
IQR | 84
(65-104) | 259
(178-389) | 512
(325-703) | 355
(162.5-627.5) | <0.001 | <0.001 | 0.003 | 0.011 | 0.694 | 0.243 | | Pre-T CXCR3+% | Median
IQR | 35
(33-38) | 40
(39-42) | 66
(60-72) | 40
(38.5-72) | <0.001 | <0.001 | 0.005 | <0.001 | 0.596 | 0.253 | | Pre-T PDL-1+CXCR3+% | Median
IQR | 25
(22-29) | 32
(27-40) | 55
(50-61) | 29
(26.5-60.5) | 0.008 | <0.001 | 0.043 | <0.001 | 0.600 | 0.242 | | Pre-T PD-1+CXCR3+% | Median
IQR | 9
(7-11) | 11
(8-15) | 12
(9-15) | 10
(9-36) | 0.017 | 0.001 | 0.092 | 0.553 | 0.629 | 0.876 | | Pre-T CD36+% | Median
IQR | 13
(12-14) | 12
(10-15) | 13
(11-15) | 12
(10-13.5) | 0.625 | 0.746 | 0.189 | 0.625 | 0.536 | 0.283 | | Pre-T CD36+PDL1+% | Median
IQR | 8
(6-9) | 9
(8-11) | 7
(6-9) | 8
(8-8.5) | 0.037 | 0.922 | 0.668 | 0.057 | 0.301 | 0.383 | | Pre-T PD-1+CD36+% | Median
IQR | 4
(3-5) | 6
(5-7) | 5
(3.8-5.3) | 5
(4.5-6.5) | 0.002 | 0.199 | 0.067 | 0.022 | 0.718 | 0.214 | | Post-T IL-19 (pg/ml) | Median
IQR | 40
(32-66) | 219
(140-551) | 560
(360-804) | 480
(175.5-678.5) | <0.001 | <0.001 | 0.005 | 0.018 | 0.359 | 0.421 | | Post-T CXCR3+% | Median
IQR | 24
(17-29) | 45
(43-49) | 78
(70-85) | 44
(30-78.5) | <0.001 | <0.001 | 0.026 | 0.013 | 0.793 | 0.153 | | Post-T PDL1+CXCR3+% | Median
IQR | 4
(2-5) | 30
(27-40) | 66
(50-74) | 32
(14-63.9) | <0.001 | <0.001 | 0.055 | 0.011 | 0.930 | 0.102 | | Post-T PD1+CXCR3+ | Median
IQR | 1
(1-3) | 13
(11-15) | 11.5
(10.5-13) | 12
(5.8-22.5) | <0.001 | <0.001 | 0.029 | 0.115 | 0.895 | 0.715 | | Post-T CD36+% | Median
IQR | 59
(54-65) | 45
(34-48) | 27
(17-34) | 41
(23-49.5) | <0.001 | <0.001 | 0.010 | 0.002 | 0.631 | 0.091 | | Post-T PDL1+CD36+% | Median
IQR | 7
(5-10) | 24
(19-28) | 17
(9.3-24.2) | 25
(8.4-27.5) | <0.001 | <0.001 | 0.026 | 0.109 | 0.827 | 0.483 | | Post-T PD-1+CD36+% | Median
IQR | 1
(1-2) | 6
(5-8) | 5
(4.5-6) | 7
(3.4-8.5) | <0.001 | <0.001 | 0.002 | 0.097 | 0.860 | 0.308 |
|
|
